Patents by Inventor Yan-ping Yang
Yan-ping Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7785609Abstract: Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of Haemophilus influenzae, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type c Haemophilus influenzae also are described.Type: GrantFiled: March 16, 2000Date of Patent: August 31, 2010Assignee: Sanofi Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20080286303Abstract: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. The Haemophilus vaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.Type: ApplicationFiled: October 23, 2007Publication date: November 20, 2008Inventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 7241449Abstract: Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.Type: GrantFiled: April 12, 1999Date of Patent: July 10, 2007Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20070031937Abstract: Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog of Haemophilus Hin47 protein, with or without leader sequence, or nucleic acid encoding high molecular weight proteins of non-typeable Haemophilus, which are hmwB, hmwC or hmwBC.Type: ApplicationFiled: March 17, 2006Publication date: February 8, 2007Inventors: Sheena Loosmore, Yan-Ping Yang
-
Patent number: 7118749Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: January 14, 2002Date of Patent: October 10, 2006Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 7015033Abstract: Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog of Haemophilus Hin47 protein, with or without leader sequence, or nucleic acid encoding high molecular weight proteins of non-typeable Haemophilus, which are hmwB, hmwC or hmwBC.Type: GrantFiled: May 25, 2000Date of Patent: March 21, 2006Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang
-
Patent number: 6974581Abstract: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. The Haemophilus vaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.Type: GrantFiled: December 15, 1998Date of Patent: December 13, 2005Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20050118189Abstract: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. The Haemophilus vaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.Type: ApplicationFiled: September 30, 2004Publication date: June 2, 2005Inventors: Sheena Loosmore, Yan-Ping Yang, Michel Klein
-
Patent number: 6849447Abstract: Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.Type: GrantFiled: December 11, 2002Date of Patent: February 1, 2005Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20030133943Abstract: Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.Type: ApplicationFiled: December 11, 2002Publication date: July 17, 2003Inventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20030088086Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: ApplicationFiled: January 14, 2002Publication date: May 8, 2003Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6440701Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.Type: GrantFiled: April 14, 1998Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6437096Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.Type: GrantFiled: January 3, 1997Date of Patent: August 20, 2002Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6432669Abstract: Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.Type: GrantFiled: December 8, 1998Date of Patent: August 13, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6391313Abstract: A multi-valent immunogenic composition confers protection on an immunized host against infection caused by both Haemophilus influenzae and Moraxella catarrhalis. Such composition comprises at least four antigens comprising at least one antigen from Haemophilus influenzae, and at least one antigen from Moraxella catarrhalis. Three of the antigens are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus and a 200 kDa outer membrane protein of Moraxella catarrhalis comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The multi-valent immunogenic composition may be combined with DTP component vaccines, which may also include non-virulent poliovirus and PRP-T, to provide a component vaccine without impairment of the immunogenic properties of the other antigens.Type: GrantFiled: July 15, 1999Date of Patent: May 21, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein, Ken Sasaki
-
Patent number: 6361779Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: May 17, 1996Date of Patent: March 26, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6358727Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbpl or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: August 5, 1996Date of Patent: March 19, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6342232Abstract: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least three different antigens of Haemophilus influenzae, two of which are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus influenzae comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The Haemophilus vaccine may be combined with DTP component vaccines, which may contain inactivated poliovirus, including type 1, type 2 and/or type 3, and/or a conjugate of a capsular polysaccharide of Haemophilus influenzae and tetanus or diphtheria toxoid, including PRP-T, to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.Type: GrantFiled: March 3, 1999Date of Patent: January 29, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6335182Abstract: Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of Haemophilus influenzae, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type c Haemophilus influenzae also are described.Type: GrantFiled: March 16, 1999Date of Patent: January 1, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan Ping Yang, Michel H. Klein
-
Patent number: 6329512Abstract: Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain.Type: GrantFiled: June 6, 1995Date of Patent: December 11, 2001Assignee: Aventis Pasteur LimitedInventors: Yan-Ping Yang, Ali Kandil, Lucy Gisonni, Raafat Emil Fahmy Fahim, Michel Henri Klein